Wire · opportunities
AI platform identifies synergistic drug combination for resistant prostate cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 October 2026 · Fusion42 review
UCLA researchers developed an AI platform called MAESTRO that integrates large language models and 3D tumor testing to identify drug combinations overcoming resistance in prostate cancer, finding berberine synergistic with enzalutamide in lab models. This platform supports more robust drug combination discovery by ranking and biologically explaining candidate compounds, validated through experiments.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 23 Oct 2026 and 25 Oct 2026.
◆ ◆ The Wire takeaway
You can use AI to identify new drug partners that work across different cancer resistance mechanisms, cutting down on trial-and-error lab work. This opens preclinical pipelines quicker if your biotech targets difficult cancer treatments.
◆ Coverage
2 sources · first reported 23 Oct 2026 · latest 25 Oct 2026
◆ Related on Wire
◆ Topics